TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.
Brief Summary: The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.


Options:
A: Arm Label: WAS patients receiving Promacta; Type: EXPERIMENTAL; Interventions: Drug: Promacta | Arm Label: WAS patients for blood drawing only; Type: EXPERIMENTAL; Interventions: Diagnostic Test: blood drawing in patients with WAS | Arm Label: healthy children for blood drawing only; Type: PLACEBO_COMPARATOR; Interventions: Diagnostic Test: blood drawing in healthy controls | Intervention Type: DRUG; Name: Promacta; Assigned to Arm(s): WAS patients receiving Promacta | Intervention Type: DIAGNOSTIC_TEST; Name: blood drawing in patients with WAS; Assigned to Arm(s): WAS patients for blood drawing only | Intervention Type: DIAGNOSTIC_TEST; Name: blood drawing in healthy controls; Assigned to Arm(s): healthy children for blood drawing only
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): Arm 1, Arm 2, Arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Intervention Type: PROCEDURE; Name: low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lower Dose Prophylactic Platelet Transfusions | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medium Dose Prophylactic Platelet Transfusions | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Higher Dose Prophylactic Platelet Transfusions | Intervention Type: PROCEDURE; Name: Medium Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lower Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Higher Dose Prophylactic Platelet Transfusions; Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
Brief Summary: The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Prebiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic; Assigned to Arm(s): Prebiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
Brief Summary: The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Intervention Type: DRUG; Name: lumacaftor; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Part A, Part B
C: Arm Label: Ataluren (PTC124®); Type: EXPERIMENTAL; Interventions: Drug: Ataluren (PTC124®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ataluren (PTC124®); Assigned to Arm(s): Ataluren (PTC124®) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Control: IVA or TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: IVA, Drug: TEZ/IVA | Arm Label: TC: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): TC: ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Control: IVA or TEZ/IVA, TC: ELX/TEZ/IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): Control: IVA or TEZ/IVA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
Brief Summary: The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 50 mg (single dose); Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 250 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 250 mg (Fed); Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: 500 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Placebo-Day 1 only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-Day 1 only | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): 10 mg, 250 mg, 50 mg, 500 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): 250 mg (Fed), 50 mg (single dose) | Intervention Type: DRUG; Name: Placebo-Day 1 only; Assigned to Arm(s): Placebo-Day 1 only
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
Brief Summary: The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 12 years and older who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Arm Label: Observational; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ivacaftor, Drug: Placebo | Arm Label: Ivacaftor; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Ivacaftor, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroregeneration Enhanced by TDCS in Stroke
Brief Summary: Testing the hypothesis that non-invasive brain stimulation by transcranial direct current stimulation (tDCS) combined with functional training in the subacute phase of first-ever stroke will enhance functional regeneration compared with a Placebo intervention.


Options:
A: Arm Label: Real; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Arm Label: sham; Type: PLACEBO_COMPARATOR; Interventions: Device: transcranial direct current stimulation tDCS, Device: transcranial magnetic stimulation TMS | Intervention Type: DEVICE; Name: transcranial direct current stimulation tDCS; Assigned to Arm(s): Real, sham | Intervention Type: DEVICE; Name: transcranial magnetic stimulation TMS; Assigned to Arm(s): Real, sham
B: Arm Label: Trunk training; Type: EXPERIMENTAL; Interventions: Other: Trunk training | Arm Label: Cognitive exercises; Type: SHAM_COMPARATOR; Interventions: Other: Cognitive exercises | Intervention Type: OTHER; Name: Trunk training; Assigned to Arm(s): Trunk training | Intervention Type: OTHER; Name: Cognitive exercises; Assigned to Arm(s): Cognitive exercises
C: Arm Label: Anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: DC-Stimulator to apply tDCS | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: DC-Stimulator to apply Sham tDCS | Intervention Type: DEVICE; Name: DC-Stimulator to apply tDCS; Assigned to Arm(s): Anodal tDCS | Intervention Type: DEVICE; Name: DC-Stimulator to apply Sham tDCS; Assigned to Arm(s): Sham tDCS
D: Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Arm Label: Conventional Paired tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional Paired tDCS | Arm Label: Conventional Unpaired tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional Unpaired tDCS | Arm Label: Late LTP-like Plasticity tDCS; Type: EXPERIMENTAL; Interventions: Device: Late LTP-like Plasticity tDCS | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham | Intervention Type: DEVICE; Name: Conventional Paired tDCS; Assigned to Arm(s): Conventional Paired tDCS | Intervention Type: DEVICE; Name: Conventional Unpaired tDCS; Assigned to Arm(s): Conventional Unpaired tDCS | Intervention Type: DEVICE; Name: Late LTP-like Plasticity tDCS; Assigned to Arm(s): Late LTP-like Plasticity tDCS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuroregeneration Enhanced by TDCS in Stroke
Brief Summary: Testing the hypothesis that non-invasive brain stimulation by transcranial direct current stimulation (tDCS) combined with functional training in the subacute phase of first-ever stroke will enhance functional regeneration compared with a Placebo intervention.


Options:
A: Arm Label: SHAM TDCS; Type: SHAM_COMPARATOR; Interventions: Device: Application of Transcranial direct current stimulation (TDCS) | Arm Label: True TDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial Direct current stimulation | Intervention Type: DEVICE; Name: Application of Transcranial direct current stimulation (TDCS); Assigned to Arm(s): SHAM TDCS | Intervention Type: DEVICE; Name: Transcranial Direct current stimulation; Assigned to Arm(s): True TDCS
B: Arm Label: tDCS + robotic arm therapy; Type: EXPERIMENTAL; Interventions: Device: Transcranial Direct Current Stimulation (tDCS) | Arm Label: tDCS sham + robotic arm therapy; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo sham | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation (tDCS); Assigned to Arm(s): tDCS + robotic arm therapy | Intervention Type: DEVICE; Name: Placebo sham; Assigned to Arm(s): tDCS sham + robotic arm therapy
C: Arm Label: Anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: DC-Stimulator to apply tDCS | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: DC-Stimulator to apply Sham tDCS | Intervention Type: DEVICE; Name: DC-Stimulator to apply tDCS; Assigned to Arm(s): Anodal tDCS | Intervention Type: DEVICE; Name: DC-Stimulator to apply Sham tDCS; Assigned to Arm(s): Sham tDCS
D: Arm Label: tDCS + physical therapy; Type: EXPERIMENTAL; Interventions: Device: tDCS + physical therapy | Arm Label: Sham tDCS + physical therapy; Type: SHAM_COMPARATOR; Interventions: Device: tDCS + physical therapy | Intervention Type: DEVICE; Name: tDCS + physical therapy; Assigned to Arm(s): Sham tDCS + physical therapy, tDCS + physical therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects Aged 6 to 11 Years With Cystic Fibrosis and the G551D Mutation
Brief Summary: The purpose of this study was to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic adenosine monophosphate (AMP)-dependent protein kinase A (PKA) activation.


Options:
A: Arm Label: VX-770; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): VX-770
B: Arm Label: VX-770; Type: EXPERIMENTAL; Interventions: Drug: VX-770, Drug: Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): VX-770 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-770
C: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Double-blind, Double-dummy, Randomized, Controlled, Parallel-group Study to Assess Efficacy and Safety of SH T00658ID Compared to SH D593B in the Treatment of Primary Dysmenorrhea
Brief Summary: To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.


Options:
A: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Qlarista Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: estradiol valerate/dienogest | Arm Label: Yasmin Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ethinylestradiol and drospirenone | Intervention Type: DRUG; Name: estradiol valerate/dienogest; Assigned to Arm(s): Qlarista Group | Intervention Type: DRUG; Name: ethinylestradiol and drospirenone; Assigned to Arm(s): Yasmin Group
C: Arm Label: NPC-01; Type: EXPERIMENTAL; Interventions: Drug: NPC-01 | Arm Label: IKH-01; Type: ACTIVE_COMPARATOR; Interventions: Drug: IKH-01 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NPC-01; Assigned to Arm(s): NPC-01 | Intervention Type: DRUG; Name: IKH-01; Assigned to Arm(s): IKH-01 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Drug: Placebo Match to SH T00658ID | Arm Label: Ethinyl estradiol, Levonorgestrel (Miranova); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ethinyl estradiol, Levonorgestrel (Miranova), Drug: Placebo Match to SH D593B | Intervention Type: DRUG; Name: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Ethinyl estradiol, Levonorgestrel (Miranova); Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova) | Intervention Type: DRUG; Name: Placebo Match to SH T00658ID; Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo Match to SH D593B; Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova)

Answer: D